Australia's CSL sees 44% profit growth
This article was originally published in Scrip
Executive Summary
Australia's CSL, the world's second-largest plasma product company, posted a 44% growth in net profit to A$502 million ($321 million) for the six months ended December 31st. The results were driven by strong sales and currency benefits.